MedTrace Logo

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

NCT02832999 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic. Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day changes in insulin secretion and insulin sensitivity.

Conditions

Interventions

DRUG

sub cutaneous liraglutide

Liraglutide 1.2mg/day

DRUG

Oral Vildagliptin

Vildagliptin 50mg/day

Sponsors & Collaborators

  • University of Yaounde 1

    collaborator OTHER

  • University of Buea

    collaborator OTHER

  • Yaounde Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Eugène Sobngwi · Yaounde Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • Cameroon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832999 on ClinicalTrials.gov